


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: <u>August 13, 2010</u> (use as many sheets as necessary)		Application Number	09/622,646
		Filing Date	2/25/1999
		First Named Inventor	Yasuko OZAKI
		Art Unit	1641
		Examiner Name	Christine E. FOSTER
Sheet 1 of 3	Attorney Docket Number	053466-0286	



U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	E1	2006/0153883 A1	07/13/2006	Kwee et al.	
	E2	7,252,996 B2	08/07/2007	Boccaccio et al.	

UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Application Document Serial Number-Kind Code ² (if known)	Filing Date of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	E3	EP 1 059 533 A1	12/13/2000	Chugai Seiyaku Kabushiki Kaisha	
	E4	WO 01/77362 A1	10/18/2001	Chugai Seiyaku Kabushiki Kaisha	A

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	E5	CHIRIVA-INTERNATI et al., "Pulsing dendritic cells via an adeno-associated virus/HM1.24 recombinant generates rapid, significant cytotoxic T lymphocyte and interferon activity against multiple myeloma and synthetic HM1.24-positive autologous targets," Cancer Gene Therapy, December 2001, 8(supp2):S27, Abstract PD-88.			
	E6	CHIRIVA-INTERNATI, Maurizio et al., "Sperm protein 17 (Sp17) is a suitable target for immunotherapy of multiple myeloma", BLOOD, Vol. 100, No. 3, pgs. 961-965, August 1, 2002.			
	E7	CONDON, Cal et al, "DNA-based immunization by <i>in vivo</i> transfection of dendritic cells", NATURE MEDICINE, Vol. 2, No. 10, pgs. 1122-1128, October 1996.			

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: <u>August 13, 2010</u> (use as many sheets as necessary)		Application Number	09/622,646
		Filing Date	2/25/1999
		First Named Inventor	Yasuko OZAKI
		Art Unit	1641
		Examiner Name	Christine E. FOSTER
Sheet 2 of 3	Attorney Docket Number	053466-0286	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	E8	DI NICOLA et al., "Gene Transfer into human dendritic antigen-presenting cells by vaccinia virus and adenovirus vectors", 1998, Cancer Gene Therapy, Vol. 5, No. 6, pgs. 350-356.	
	E9	EVANS et al., "Vaccine therapy for cancer - fact or fiction?", Q.J. Med., 1999, 92:299-307.	
	E10	GONG, Jianlin et al., "Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells", NATURE MEDICINE, Vol. 3, No. 5, pgs. 558-561, May 1997.	
	E11	HUNDEMER et al., "Identification of T Cell Epitopes within the Plasmacell Antigen HM1.24", 2002, Blood, Vol. 100, No. 11, pg. Abstract No. 5088, XP009063835.	
	E12	KOMENAKA et al., "Immunotherapy for Melanoma," Clinics in Dermatology, 2004, 22:251-265.	
	E13	OHTOMO et al., "Molecular Cloning and Characterization of a Surface Antigen Preferentially Overexpressed on Multiple Myeloma Cells", Biochemical and Biophysical Research Communications, 1999, Vol. 258, No. 3, pgs. 583-591.	
	E14	OZAKI et al., "Humanized Anti-HM1.24 Antibody Mediates Myeloma Cell Cytotoxicity That is Enhanced by Cytokine Stimulation of Effector Cells", Blood, 1999, Vol. 93, No. 11, pgs. 3922-3930.	
	E15	PORGADOR, Angel et al., "Bone Marrow-generated Dendritic Cells Pulsed with a Class I-restricted Peptide Are Potent Inducers of Cytotoxic T Lymphocytes", J. EXP. MED., Vol. 182, No. 1, pgs. 255-260, July 1995.	
	E16	REW, et al., "Potent anti-tumour cytotoxic T lymphocytes directed against the myeloma antigen HM1.24", Blood, 2003, Vol. 102, No. 11, pg. 112A, XP009063769.	
	E17	SONG, Wenru et al., "Dendritic Cells Genetically Modified with an Adenovirus Vector Encoding the cDNA for a Model Antigen Induce Protective and Therapeutic Antitumor Immunity", J. EXP. MED., Vol. 186, No. 8, pgs. 1247-1256, 1997.	
	E18	SPECHT, Jennifer M. et al., "Dendritic Cells Retrovirally Transduced with a Model Antigen Gene are Therapeutically Effective against Established Pulmonary Metastases", J. EXP. MED., Vol. 186, No. 8, pgs. 1213-1221, 1997.	
	E19	STEVENSON, Freda K., "Update on cancer vaccines," Curr. Opin. Oncol., 2005, 17:573-577.	
	E20	SYRENGELAS, Anthanasia D. et al., "DNA immunization induces protective immunity against B-cell lymphoma", NATURE MEDICINE, Vol. 2, No. 9, pgs. 1038-1041, September 1996.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: <u>August 13, 2010</u> <i>(use as many sheets as necessary)</i>		Application Number	09/622,646
		Filing Date	2/25/1999
		First Named Inventor	Yasuko OZAKI
		Art Unit	1641
		Examiner Name	Christine E. FOSTER
Sheet	3	of	3
		Attorney Docket Number	053466-0286

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	E21	SZABOLCS, Paul et al., "Retrovirally Transduced Human Dendritic Cells Express a Normal Phenotype and Potent T-Cell Stimulatory Capacity", <i>BLOOD</i> , Vol. 90, No. 6, pgs. 2160-2167, September 1997.	
	E22	THURNER, Beatrice et al., "Vaccination with Mage-3A1 Peptide-pulsed Mature, Monocyte-derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV Melanoma", <i>J. EXP. MED.</i> , Vol. 190, No. 11, pgs. 1669-1678, 1999.	
	E23	TREON, Steven P., et al., "Immunotherapeutic Strategies for the Treatment of Plasma Cell Malignancies", <i>SEMINARS IN ONCOLOGY</i> , Vol. 27, No. 5, pgs. 598-613, 2000.	
	E24	ZETTLMEISL et al., "Expression and Characterization of Human CD4: Immunoglobulin Fusion Proteins," <i>DNA and Cell Biology</i> , 1990, 9(5):347-353.	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.